| Poor outcomes associated with+ der (22) t (9; 22) and− 9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a … NJ Short, HM Kantarjian, K Sasaki, F Ravandi, H Ko, C Cameron Yin, ... American journal of hematology 92 (3), 238-243, 2017 | 51 | 2017 |
| Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma NJ Short, HM Kantarjian, H Ko, JD Khoury, F Ravandi, DA Thomas, ... American journal of hematology 92 (6), E114, 2017 | 48 | 2017 |
| Clinical utility of 18F-FDG PET/CT in staging localized breast cancer before initiating preoperative systemic therapy H Ko, Y Baghdadi, C Love, JA Sparano Journal of the National Comprehensive Cancer Network 18 (9), 1240-1246, 2020 | 39 | 2020 |
| Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature H Ko, H Maymani, C Rojas-Hernandez Journal of Medical Case Reports 10, 1-4, 2016 | 39 | 2016 |
| Predictors of survival in patients with advanced gastrointestinal malignancies admitted to the intensive care unit H Ko, M Yan, R Gupta, K Kebbel, A Maiti, J Song, J Nates, MJ Overman The oncologist 24 (4), 483-490, 2019 | 13 | 2019 |
| Older age and increased neutrophil-to-lymphocyte ratio (NLR) are predictors of mortality in a multiethnic urban cohort of hematologic neoplasms and COVID-19 patients A D'Aiello, S Zareef, K Pradhan, A Lombardo, F Khatun, J Mustafa, ... Blood 136, 34-35, 2020 | 6 | 2020 |
| The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer MK Nesline, V Subbiah, RA Previs, KC Strickland, H Ko, P DePietro, ... Oncology and Therapy, 1-15, 2024 | 3 | 2024 |
| Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer RJ Seager, MF Senosain, E Van Roey, S Gao, P DePietro, MK Nesline, ... Journal of Translational Medicine 22 (1), 141, 2024 | 3 | 2024 |
| The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer … MK Nesline, P DePietro, M Cooper, S Zhang, S Howarth, ZD Wallen, ... Journal of Clinical Oncology 41 (16_suppl), 6506-6506, 2023 | 3 | 2023 |
| Abstract PS4-30: Neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors A Weiner, LS Munoz-Arcos, H Ko, J Anampa Cancer Research 81 (4_Supplement), PS4-30-PS4-30, 2021 | 2 | 2021 |
| Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy. H Ko, Y Baghdadi, C Love, JA Sparano Journal of Clinical Oncology 38 (15_suppl), 563-563, 2020 | 2 | 2020 |
| Clinical outcomes of acquired factor VIII inhibitors in cancer population: a systematic review HC Ko, C Rojas Hernandez, TH Oo Blood 130 (Supplement 1), 5639-5639, 2017 | 2 | 2017 |
| Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer RJ Seager, H Ko, S Pabla, MF Senosain, P Kalinski, E Van Roey, S Gao, ... Journal of Personalized Medicine 14 (5), 481, 2024 | 1 | 2024 |
| The predictive role of TNF-related genes in patients receiving immune checkpoint inhibitors OE Ababneh, S Kato, D Nishizaki, H Miyashita, S Lee, M Nesline, S Pabla, ... Cancer Research 84 (6_Supplement), 6393-6393, 2024 | 1 | 2024 |
| 87 Distinctions in Tumor Microenvironment Between PD-L1 Positive versus Negative Head and Neck Squamous Cell Carcinoma (HNSCC) KS Saini, HC Ko, ZD Wallen, MF Green, KC Strickland, RA Previs, ... Radiotherapy and Oncology 192, S20-S22, 2024 | 1 | 2024 |
| Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? H Ko, RA Previs, KC Strickland, J Klein, B Caveney, C Chiruzzi, ... Oncology and Therapy 12 (1), 13-17, 2024 | 1 | 2024 |
| Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting P Moussa, R Kurzrock, D Nishizaki, H Miyashita, S Lee, M Nikanjam, ... American Journal of Cancer Research 14 (4), 1634, 2024 | 1 | 2024 |
| LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer. R Seager, MF Senosain, E Van Roey, S Gao, P DePietro, MK Nesline, ... Journal of Clinical Oncology 41 (16_suppl), e21113-e21113, 2023 | 1 | 2023 |
| Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer HC Ko, RJ Seager, S Pabla, MF Senosain, E Van Roey, S Gao, ... Breast Cancer: Targets and Therapy, 483-495, 2024 | | 2024 |
| 1403 Comparison of tumor immune microenvironment (TME) between primary and metastatic upper gastrointestinal (GI) adenocarcinoma R Seager, S Pabla, S Mukherjee, MF Senosain, H Parikh, E Van Roey, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
